Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study.

Tatsuki IkomaToshihiko MatsumotoShogen BokuYusuke MotokiHidefumi KinoshitaHisashi KosakaMasaki KaiboriKentaro InoueMitsugu SekimotoTakuo FujisawaHiroshi IwaiMakoto NaganumaHideaki TanizakiYoji HisamatsuHidetaka OkadaTakayasu Kurata

Published in: Cancer immunology, immunotherapy : CII (2024)

IO therapy is a safe treatment option for patients > 80 years old. Furthermore, patients with elevated eosinophil counts at treatment initiation should be cautiously managed.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
patient reported outcomes
combination therapy
peripheral blood